Compounded Creams: Why Dermatologists Are Cautious

Compounded skincare sits in an unusual position: the ingredients inside are often legitimate, the prescribing doctors are real, and the patients seeking them usually have a genuine reason. The problem is the space between the ingredient and the finished product, a space that standard manufactured medicines fill with stability testing, sterility checks, and regulatory oversight. Compounded preparations largely skip that space, and that is where dermatologists' hesitation lives.

A compounded preparation is mixed by a pharmacist or compounding facility to a specific formula, usually written by a doctor for a named patient. The logic is straightforward: if a patient needs a particular combination of actives, say, a low-concentration tretinoin paired with azelaic acid and a mild steroid, and no commercial product offers that exact mix, a compounding pharmacy can make it. The same principle applies when a patient cannot tolerate a preservative in a standard formulation, or when a drug is commercially unavailable in a suitable vehicle.

This is a legitimate medical function. Compounding has been part of pharmacy practice for a long time, and for some patients it is genuinely the right route. The concern is not that compounding exists; it is that the practice has expanded well beyond these edge cases into a much broader market, often with less clinical justification and less oversight than the original use case assumed.

Manufactured pharmaceutical creams go through stability testing: a manufacturer must demonstrate that the active ingredient stays at its stated concentration, does not degrade into harmful breakdown products, and remains free of microbial contamination across the product's shelf life. Compounded preparations are not required to meet the same standard. A pharmacy may test its base formulas, but individual compounded batches are almost never independently tested for potency or sterility before they reach a patient.

This creates two practical risks. First, the concentration of the active may not match what is written on the label, either higher, which raises the risk of side effects, or lower, which means the treatment is not working as intended. Second, if sterility is compromised, a cream applied to already-inflamed or broken skin can introduce infection. Both risks are low when the compounding facility follows good practice, but neither risk exists at all in a well-manufactured commercial product.

The Indian regulatory picture adds another layer. The Drugs and Cosmetics Act governs pharmaceutical manufacturing, but compounding by a licensed pharmacist on a valid prescription occupies a grey area that is not uniformly enforced across states. A patient receiving a compounded cream in one city may have no practical way to know whether the facility preparing it meets any particular standard.

Many compounded formulas combine actives that are individually well-studied but have never been formally tested together in the same vehicle. Tretinoin and hydroquinone, for example, are both established in dermatology. A formula that puts them alongside a mid-potency corticosteroid in a single cream may work well for some patients, but the interaction between the three, how they affect each other's penetration, how the steroid modifies the inflammatory response that tretinoin can trigger, what happens to skin barrier function over months of use, has not been studied in that specific combination.

Dermatologists who are cautious about compounding are not dismissing the ingredients. They are pointing out that the combination is being prescribed based on clinical reasoning and experience, not on controlled evidence. That is sometimes the right call. It is also a call that should be made by a dermatologist who has examined the patient and can monitor for side effects, not by a compounding pharmacy offering a standard formula to anyone who enquires.

Compounded creams are a reasonable option when a commercial alternative does not exist, when a patient has a documented sensitivity to an excipient in the standard product, or when a dermatologist has a specific clinical reason that a fixed-dose commercial product cannot address. In these situations, the benefit of the tailored formulation outweighs the absence of formal stability data.

They are a less reasonable option when the driver is cost, convenience, or the appeal of a bespoke formula, and when a commercially manufactured equivalent exists. They are particularly worth scrutinising when the prescription comes without a clinical examination, when the formula is a standard house blend rather than something genuinely individualised, or when the patient has a compromised skin barrier, as in active eczema or a post-procedure state, where sterility matters most.

Anyone considering a compounded preparation should have that conversation with a qualified dermatologist, not only with the prescribing source. The question to ask is not whether the ingredients are legitimate but whether this specific combination, from this specific facility, is the right choice for this specific skin condition, and whether there is a reason a manufactured product cannot do the same job.

The ingredients in most compounded creams are not the problem. The problem is the assumption that a legitimate ingredient list guarantees a safe and effective finished product. Between the formula and the patient's skin, there is a manufacturing step that matters more than it looks.

Discover expert advice and the latest updates in Skin Care, Hair Care, Wellness, Dermatology, and more at Stay Young guide to lasting beauty and holistic health!